UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa

UCB said the US Food and Drug Administration has approved Bimzelx for the treatment of adults with moderate to severe Hidradenitis Suppurativa (HS), according to a company statement.

• Approval is supported by data from the two Phase 3 studies, in which Bimzelx improved the signs and symptoms vs. placebo at Week 16
• NOTE: Hidradenitis Suppurativa is a chronic and potentially debilitating inflammatory skin disease
• Approval marks the fifth indication for Bimzelx in the US

To contact the reporter on this story:
Charlotte Hughes-Morgan in London at chughesmorga@bloomberg.net

To contact the editors responsible for this story:
Cagan Koc at ckoc2@bloomberg.net ...